A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Abroad (travel likely)Recruiting
Conditions
Plaque Psoriasis · Metabolic Dysfunction-Associated Steatotic Liver Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Novartis Investigative Site, Badalona, Barcelona, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Málaga, Spain
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals